Consilium scientific

We are building a world where Clinical Research is based on integrity, transparency and methodological rigor to enable evidenced and accessible Healthcare for All



Benefits and risks for screening: cancer as an exemplar  Sign up


HTA in Question: Evaluation Process and Methods


Clinical trial results reporting on EudraCT made easy  Sign up

Сonsilium Scientific is a non-profit research and educational organization dedicated to informing and enacting health policy change in the UK and around the world.


We aspire to transform clinical research and healthcare by:

  • delivering and enabling initiatives on scientific integrity and transparency

  • educating the new generation of professionals to transform current culture

  • enabling policy change through high quality evidence

  • bringing together organisations to amplify our efforts

  • engaging patients and carers in everything we do.

Why Consilium?

  • There is a lot of waste in clinical research
  • Many trials are poorly designed
  • We lack trials answering clinically relevant questions
  • Not all trials are being registered
  • Results of trials are not routinely and properly reported to patients
  • We lack replication studies
  • Research data are rarely being shared
  • Conflict of interest in medicine and clinical research is overwhelming
  • Many mediocre medicines enter the market
  • We lack transparency of clinical and price data
  • Drug prices are too high
  • Publishing model is broken

...because patients deserve better


Evidence Generation

Health on Trial


Quality of Clinical data

Policy and advocacy work

Knowledge Sharing

Seminars & Events

Workshops & Courses

Patient Engagement


Consilium Incubator



Support of like-minded organisations

Joint initiatives



Eric Low, OBE

Eric has worked in the fields of medical research, market access and patient organisations for over 25 years. He set up Myeloma UK in 1996, leading the organisation as Chief Executive until 2017.

He currently runs a consultancy business specialising primarily in strategic market access, life sciences and healthcare policy, patient and patient group engagement.

Eric is committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of cancer and rare diseases. He has a strong track record of delivery and success for example in building multi-stakeholder research collaborations, patient coalitions, market access strategies, changing policy, and generally in delivering innovative solutions to complex issues, challenges and barriers standing in the way of progress.

Eric also holds several Board, honorary, advisory and voluntary positions. He also advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.


John Hickman, PhD

Prof Hickman is an internationally known scientist who trained in pharmacy and organic chemistry in Birmingham UK. After a postdoctoral fellowship at the Institute of Cancer Research London, he held University posts in molecular pharmacology in Liverpool, Birmingham and Manchester and as a visiting scientist at Yale University. As a Director of the Cancer Research Campaign’s (now CRUK) Experimental Chemotherapy group in Birmingham he was lead pharmacologist for the discovery of the drug Temozolomide used to treat brain tumours. He worked on the role of apoptosis in determining anticancer drug sensitivity and resistance, particularly the role of the BCL-2 family of proteins. He talked about his work on apoptosis in 1998 at the invitation of the Nobel Forum in Stockholm and was invited again to speak at a Nobel Symposium in 2018, this time on personalised cancer medicine. Professor Hickman moved to Paris in 2000 to direct cancer drug discovery at Servier. He retired in 2010 and then coordinated the European Union Innovative Medicines Initiative (IMI) consortium PREDECT. In March 2018, he co-organised an international meeting at the Francis Crick Institute entitled “The Challenges Preventing Cancer Cure”.



Kalipso Chalkidou, MD, PhD

Kalipso Chalkidou is the founding Head of the Global Fund’s Health Financing Department, responsible for driving the domestic resource mobilisation and blended financing agenda and enhancing the GF’s application of value for money principles. Prior to this she was the Director of Global Health Policy and a Senior Fellow at the Center for Global Development and  Director of Global Health and Development Group at the Institute of Global Health Innovation, Imperial College London, helping governments build technical and institutional capacity for improving the value for money of their healthcare investment.

She has been involved in the Chinese rural health reform and also in national health reform projects in the USA, India, Colombia, Turkey and the Middle East, working with the World Bank, PAHO, DFID and the Inter-American Development Bank as well as national governments. Between 2008 and 2016 she founded and ran NICE International, a non-profit group within the UK’s National Institute for Health and Care Excellence (NICE). 

Kalipso is a Visiting Professor at Imperial College London and at Kings College London.




UK Office

Mabledon Place
Hamilton House
London WC1H 9BB

US Office

9711 Washingtonian Boulevard
Gaithersburg, MD


Our partners



logo cancer en

logo cancer en

We Support

plenary session



© 2022. Consilium-Scientific™. All Rights Reserved.